Rapidly Progressive Neurodegenerative Dementias
Arch Neurol 66:201-207, Josephs,K.A.,et al, 2009
Alzheimers Disease
Lancet 397:1577-1590, Scheltens, P.,et al, 2021
The Effects of Long-Term Medication Use in Alzheimer Disease
Neurol 96:e2247-e2250, Karceski, S., 2021
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
Neurodegenerative causes of death among retired National Football League Players
Neurol 79:1970-1974, Lehman, E.,et al, 2012
Rapidly Progressive Alzheimer Disease
Arch Neurol 68:1124-1130, Schmidt, C.,et al, 2011
Long-Term Effects of the Concomitant Use of Memantine with Cholinesterase Inhibition in Alzheimer Disease
JNNP 80:600-607, Lopez,O.L.,et al, 2009
The Clinical Course of Advanced Dementia
NEJM 361:1529-1538, 1595, Mitchell,S.,et al, 2009
Survival Times in People with Dementia: Analysis From Population Based Cohort Study With 14 Year Follow-Up
BMJ 336:258-262,225, Xie,J.,et al, 2008
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Estimating Prognosis for Nursing Home Residents with Advanced Dementia
JAMA 291:2734-2740, Mitchell,S.L.,et al, 2004
Natural History of Mild Cognitive Impairment in Older Persons
Neurol 59:198-205, Bennett,D.A.,et al, 2002
A Reevaluation of the Duration of Survival After the Onset of Dementia
NEJM 344:1111-1116, Wolfson,C.,et al, 2001
Survival in End-Stage Dementia Following Acute Illness
JAMA 284: 47-52, 87, Morrison,R.S. & Siu,A.L., 2000
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Increased Risk of Mortality in Alzheimer's Disease Patients with Higher Education
Neurol 49:798-802, Geerlings,M.I.,et al, 1997
Long-Term Tacrine (Cognex) Treatment:Effects on Nursing Home Placement and Mortality
Neurol 47:166-177, Knopman,D.,et al, 1996
AIDS in the Elderly:New York City Vital Statistics
J Emerg Med 14:19-23, Gaeta,T.J.,et al, 1996
Increased Risk of Mortality in Alzheimer's Disease Patients with More Advanced Educataional and Occupational Attainment
Ann Neurol 37:590-595, Stern,Y.,et al, 1995
Chromosome 14-Encoded Alzheimer's Disease:Genetic and Clinicopathological Description
Ann Neurol 36:362-367, Haltia,M.,et al, 1994
Medical Aspects of the Persistent Vegetative State
NEJM 330:1499-1508, 1572-15791994., Annas,G.J.,et al, 1994
A Population-Based Study of Dementia in 85-Year-Olds
NEJM 328:153-158, 203-2051993., Skoog,I.,et al, 1993
Time Until Institutionalization and Death in Patients with Dementia
Arch Neurol 50:643-650, Brodaty,H.,et al, 1993
The Older Driver, Clinical Assessment and Injury Prevention
Arch Int Med 152:735-740, Underwood,M., 1992
Dementia:Age-Dependent Incidence, Prevalence, and Mortality in the Old Old
Arch Int Med 151:989-992, Aronson,M.K.,et al, 1991
Clinical Characteristics of Patients in the Persistent Vegetative State
Arch Int Med 151:930-932, 855-8561991., Tresch,D.D.,et al, 1991
Survival of Outpatients with Alzheimers-Type Dementia
Ann Int Med 113:429-434, Walsh,J.S.,et al, 1990
A Controlled Study of Survival with Dementia
Arch Neurol 44:1122-1126, Martin,D.C.,et al, 1987
Early-Onset Alzheimer's Disease:Clinical Predictors of Institutionalization & Death
Neurol 37:980-984, Heyman,A.,et al, 1987
Amyloid-Related Imaging Abnormalities (ARIA) in Clinical Trials of Gantenerumab in Early Alzheimer Disease
JAMA Neurol 92:19-29, Salloway,S.,et al, 2025
Alzheimers Disease Biomarkers - Timing is Everything
NEJM 390:761-763, Mayeux,R., 2024
Repurposing Erectile Dysfunction Medication for Alzheimer Disease Prevention
Neurol 102:e209180, Yasara,S., & Nidadavolu,L., 2024
Lecanemab for Alzheimer Disease, Is It Worth It?
Neurol 102:e209265, Nelson,S.E. & Lopez,O.L., 2024
Tau Positron Emission Tomography for Predicting Dementia in Individuals with Mild Cognitive Impairment
JAMA Neurol 81:845-856, Groot,C.,et al, 2024
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Lecanemab in Early Alzheimers Disease
NEJM 388:9-21,80, van Dyck,A.H.,et al, 2023
Cognitive and Clinical Characteristics of Patients with Limbic-Predominant Age-Related TDP-43 Encephalopathy
Neurol 100:e2027-e2035, Pagnotti,R.M.B.,et al, 2023
Donanemab in Early Symptomatic Alzheimer Disease, The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
JAMA 330:512-517, 510, Sims,J.R.,et al, 2023
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Brexpiprazole for the Treatment of Agitation and Aggression in Alzheimers Disease
JAMA Neurol 80:1272-1273, Ballard,C., 2023
Amyloid-Related Imaging Abnormalities:An Update
AJR 220:562-575, Roytman,M.,et al, 2023
Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients with Early Alzheimer Disease
Neurol 98:e968-e977, Whittington, M.D.,et al, 2022
An 80-Year-Old Woman with a Homonymous Hemianopsia
Neurol 99:713-717, Tajfirouz, D.,et al, 2022
Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist
AJNR 42:998-1007, Oldan, J.D.,et al, 2021
Controversy and Progress in Alzheimers Disease - FDA Approval of Aducanumab
NEJM 385:doi:10.1056/NEJMp2111320, Rabinovici, G.D., 2021
Aducanumab: What About the Patient?
Ann Neurol 90:334-335, Petersen, R.C., 2021